Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Andrew Dudum, CEO of Hims & Hers Health Inc. (NYSE:HIMS), recently sold a significant portion of his holdings in the company.

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most ...

In “The Harder I Fight the More I Love You,” the singer and songwriter outlines the personal and professional challenges that ...

Hims & Hers (HIMS) is down -6.5%, or -$1.81 to $26.13.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top ...